Logo

Perlegen and GSK Launch Pharmacogenomics Collaboration

Sep 18, 2002

NEW YORK, Sept. 18-Perlegen will work with GlaxoSmithKline in a whole genome scanning project to identify drug response markers, the company said today.

 

The collaboration is based upon Perlegen's technique for using high-density microarrays for sequencing, SNP discovery, and haplotype identification. It will "complement" GSK's in-house research, a company representative said in a statement.

 

Using this technique, Perlegen says it can sequence an entire genome in ten days.

 

The companies did not disclose the financial details of this collaboration.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.